Lambert-Eaton Myasthenic Syndrome (LEMS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Lambert-Eaton Myasthenic Syndrome (LEMS)

Lambert-Eaton Myasthenic Syndrome (LEMS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune, presynaptic disorder of neuromuscular transmission characterized by fluctuating muscle weakness and autonomic dysfunction frequently associated with small-cell lung cancer (SCLC). Around 90% of LEMS patients have pathogenic antibodies against the presynaptic P/Q-type voltage-gate calcium channel (VGCC). Dysfunction or decrease in number of these channels inhibits release of acetylcholine from the presynaptic endplate, resulting in impaired neuromuscular transmission and muscle weakness.

According to Thelansis the prevalence of Lambert-Eaton Myasthenic Syndrome (LEMS)  is estimated to be between 1/250,000- 1/333,300 worldwide. There are approximately 400 known cases of LEMS in the United States.

Competitive landscape of Lambert-Eaton Myasthenic Syndrome (LEMS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Lambert-Eaton Myasthenic Syndrome (LEMS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Lambert-Eaton Myasthenic Syndrome (LEMS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Lambert-Eaton Myasthenic Syndrome (LEMS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company         Partner        Phase

1        Firdapse        Catalyst Pharmaceuticals, Inc.        Jazz Pharmaceuticals        Approved

2        Ruzurgi        Jacobus Pharmaceutical Co. Inc        N/A        Approved"